Premier Cross-border Private Equity Investors
Market Opportunity in China
Our partners and advisors average over two decades of direct experience investing and operating in China. We aim to leverage our expertise in cross-border investing, deal-structuring and operational execution to achieve help our portfolio companies penetrate the Chinese market.
Drastic Rise of Non-communicable Diseases (NCDs)
NCDs are responsible for 89% of all deaths in China. This is likely due to key factors such as the high proportion of daily smokers and increasingly unhealthy dietary habits.
Rapidly Aging Chinese Population
About 10.6% of China’s population is over 65 years old. The United Nations estimates that by 2050, more than
people in China will be aged 60 or over, bringing the number of working individuals per elderly individual from 6.9 in 2015 to 2.1 in 2050.
China’s State Council Healthcare Market Objectives
(in Billion CNY)
China’s ambitious healthcare reformation will support robust growth in domestic healthcare expenditure and foreign investment, which is reflected in the “Plan of Health China 2030".
Why Invest in Cross-border Healthcare Now?
Leveraging our cross-border expertise, vast network of strategic industry contacts, and deep knowledge of the healthcare industry, we intend to achieve compelling risk-adjusted returns for our investors. The fund has identified a handful of attractive sub-sectors that we believe are best-positioned to capture the rapid growth and transformation of both the Chinese and U.S healthcare markets.
The Chinese government has been supportive of foreign product entry, evidenced by the number of foreign drug applications increasing 2.85x from 2016 to 2017.
Chinese VCs have contributed roughly 43% of the capital inflow in the US healthcare sector in 2018, up from just 11% in 2016.
The healthcare sector has consistently outperformed in late stages, as healthcare related revenues are more insulated from economic underperformance.
152 W57th Street, Carnegie Hall Tower, 49th Floor, New York